GOG studies Active and Just Completed – Flashcards

GOG263: RT vs CCRT in intermediate risk cervix cancer after hysterectomy--gog92 pt population *active* GOG0724:ChemoRT with and without adjuvant chemotherapy in high risk cervix cancer after hysterectomy: gog109 pt population *active*

GOG274:A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: GOG COLLABORATION WITH THE OUTBACK TRIAL (ANZGOG 0902 OUTBACK trial:Chemoradiotherapy +/- adjuvant chemotherapy TIME-C trial:RTOG: randomized phase III trial of standard EBRT vs. IMRT in postop EndoCA and Cvx ca that require RT.

GOG278:Conservative surgery (cone/nodes or hyst/(nodes) in early stage cervical cancer. (evaluation of physical function and QOL)--similar to SHAPE trial SHAPE trial: randomized trial of rad hyst/PLND vs. simple hyst/PLND in low risk early stage cvx cancer (Simple Hyst And Pelvic nodes in Early cvx cancer =S H A P E)

GOG279:Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in Treatment of Locally Adv. SC C of the Vulva remember GOG205 with chemoRT in advanced vulvar cancer with cddp and then resection (like GOG101) *interesting thing is that vulvar cancer goes from rt to ebrt to ccrt now moving into CCIMRT....*

GOG242: phase II study for low risk nonmetastatic GTN with upfront repeat D&C. showed decrease in need for chemotherapy by about 36%. GOG275:A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia *active*

GOG261 (gog161 if only for uterus): phase III trial of TC vs. IFEX/taxol in chemotherapy naive pts with newly dx stage I-IV, recurrent or persistent CS of uterus (and ovary too)--closed 3/2014 GOG249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer-closed PORTEC3: Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma--closed GOG258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Cancer GOG238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus

GOG261: A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary---Closed 3/2014

GOG250: Gemzar/taxotere with/without bev in pt with advanced/recurrent LMS--closed and was a negative study for Bev. GOG277: phase III trial of gemzar/taxotere followed by doxorubicin vs. observation in uterine limited/stage I LMS

GOG213: a randomized phase III trial comparing secondary CRS vs. no surgery and then comparing chemo with bev vs. chemo w/o bev among pts that failed 1st line therapy GOG241: MEOC study open label: phase III trial in mucinous ovarian cancer comparing TC +/- bev VS. oxaliplatin/capecitabine +/-bev GOG262:A Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab: completed GOG273: chemo toxicity on QOL in older pts with EOC: completed TRINOVA3/GOG3001: phase III study with TC +/- amg386 as 1st line treatment in FIGO stage III-IV EOCs

studies are in the works that will compare neoadjuvant chemo followed by RT to standard CCRT to CCRT with adjuvant chemo looking to see if neoadjuvant can shrink primary tumor and make RT better or if chemo after RT is better for the higher risk groups.

low risk nonmetastatic GTN Actively accruing: Pulsed Act-D v. 2 different MTX arms MTX: 5d mtx every two weeks or 50mg weekly or 8d trial